Exchange: NASDAQ·Updated 07:45 PM EDT
NPCE logo

NPCENeuroPace Inc

$15.89
$0.64
(3.87%)
Today
Closed $15.89
$0.16
(1.01%)
After Hours
EarningsAug 11
Mkt Cap$563.57M
Vol163,219.00
News
all
press releases
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant(TM)
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
News Placeholder
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.
Zacks
News Placeholder
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.
Zacks
News Placeholder
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 June 2, 2026 in...
Business Wire
News Placeholder
NeuroPace Announces FDA Approval of ECoG Assistant, Advancing AI-Driven Epilepsy Care
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPaces broader AI platform...
Business Wire
News Placeholder
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
Zacks
News Placeholder
NPCE Explains How NeuroPace's RNS System Makes Money
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
Zacks
News Placeholder
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
Zacks
<
1
2
...
>

Advertisement|Remove ads.